Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Role of FLT3 inhibitors as maintenance following transplant in AML

Mark Levis • 6 Dec 2018
ASH 2018
Acute Myeloid Leukemia Leukemia Midostaurin Sorafenib

Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the role of FLT3 inhibitors as a maintenance therapy following transplant in acute myeloid leukemia (AML).

More from Mark Levis

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
1:03
Personalizing AML treatment by targeting MRD mutations
Mark Levis • 10 Dec 2023
2:00
FLT3-ITD-specific MRD predicts outcomes of chemotherapy in AML
Mark Levis • 10 Dec 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals